These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21827695)

  • 1. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer.
    Serrano D; Bleau AM; Fernandez-Garcia I; Fernandez-Marcelo T; Iniesta P; Ortiz-de-Solorzano C; Calvo A
    Mol Cancer; 2011 Aug; 10():96. PubMed ID: 21827695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment with flavonoid morin and telomerase inhibitor MST‑312 reduces cancer stem cell traits by targeting STAT3 and telomerase.
    Chung SS; Oliva B; Dwabe S; Vadgama JV
    Int J Oncol; 2016 Aug; 49(2):487-98. PubMed ID: 27279256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells.
    Di Martile M; Desideri M; De Luca T; Gabellini C; Buglioni S; Eramo A; Sette G; Milella M; Rotili D; Mai A; Carradori S; Secci D; De Maria R; Del Bufalo D; Trisciuoglio D
    Oncotarget; 2016 Mar; 7(10):11332-48. PubMed ID: 26870991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/β-catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas.
    Huang WC; Kuo KT; Adebayo BO; Wang CH; Chen YJ; Jin K; Tsai TH; Yeh CT
    J Nutr Biochem; 2018 Apr; 54():140-150. PubMed ID: 29414668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.
    Sullivan JP; Spinola M; Dodge M; Raso MG; Behrens C; Gao B; Schuster K; Shao C; Larsen JE; Sullivan LA; Honorio S; Xie Y; Scaglioni PP; DiMaio JM; Gazdar AF; Shay JW; Wistuba II; Minna JD
    Cancer Res; 2010 Dec; 70(23):9937-48. PubMed ID: 21118965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
    Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
    Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.
    Jiang F; Qiu Q; Khanna A; Todd NW; Deepak J; Xing L; Wang H; Liu Z; Su Y; Stass SA; Katz RL
    Mol Cancer Res; 2009 Mar; 7(3):330-8. PubMed ID: 19276181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
    Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
    J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines.
    Abdul Satar N; Ismail MN; Yahaya BH
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33670440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.
    Prud'homme GJ; Glinka Y; Toulina A; Ace O; Subramaniam V; Jothy S
    PLoS One; 2010 Nov; 5(11):e13831. PubMed ID: 21072210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients.
    de Aberasturi AL; Redrado M; Villalba M; Larzabal L; Pajares MJ; Garcia J; Evans SR; Garcia-Ros D; Bodegas ME; Lopez L; Montuenga L; Calvo A
    Cancer Lett; 2016 Jan; 370(2):165-76. PubMed ID: 26546046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells.
    Liu J; Xiao Z; Wong SK; Tin VP; Ho KY; Wang J; Sham MH; Wong MP
    Oncotarget; 2013 Oct; 4(10):1698-1711. PubMed ID: 24091605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway.
    Shao C; Sullivan JP; Girard L; Augustyn A; Yenerall P; Rodriguez-Canales J; Liu H; Behrens C; Shay JW; Wistuba II; Minna JD
    Clin Cancer Res; 2014 Aug; 20(15):4154-66. PubMed ID: 24907115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
    Wang L; Park P; La Marca F; Than KD; Lin CY
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1013-24. PubMed ID: 25431339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
    Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells.
    Shanmugam G; Mohan A; Kumari K; Louis JM; Soumya Krishnan U; Balagopal PG; George NA; Sebastian P; Maliekal TT
    Exp Cell Res; 2019 Oct; 383(2):111551. PubMed ID: 31401066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.